Please assess the completion status of the following clinical trial:

Trial Title: Nabilone for Non-motor Symptoms in Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~In order to be eligible for the study subjects must meet all inclusion criteria:~1. Age ≥30 years~2. Diagnosis of Parkinson´s Disease (PD): PD should be either de novo or on stable medication without disturbing motor fluctuations or dyskinesia.~3. NMS with a score of ≥4 on MDS-UPDRS Part 1. One of the following domains have to be affected with a score ≥2: 1.4 (anxious mood) or 1.9 (pain)~4. On a stable regimen of anti-parkinson medications for at least 30 days prior to screening and willing to continue the same doses and regimens during study participation~5. Any other current and allowed prescription/non-prescription medications and/or nutritional supplements taken regularly must have been at a stable dose and regimen for at least 30 days prior to screening, and subject must be willing to continue the same doses and regimens during study participation~6. Patient is informed and had enough time and opportunity to think about his/her participation in the study and has signed a current Institutional Review Board-approved informed consent form~7. Contraception~   1. Women of childbearing potential must use or attest an acceptable method\* of contraception starting 4 weeks prior to study drug administration and for a minimum of 1 month after study completion.~  2. Men with a potentially fertile partner must be willing to use an acceptable method of contraception for the duration of the study and for 3 months after study drug discontinuation or have had a vasectomy.~Exclusion Criteria:~Patients with any of the following characteristics will be excluded from entering the study:~1. Patient previously participated in any study with nabilone.~2. Current use of cannabinoids or use of cannabinoids within 30 days prior to screening.~3. Patient is currently participating in or has participated in another study of investigational products within 30 days prior to screening.~4. Patient has any form of secondary or atypical parkinsonism (e.g., drug-induced, post stroke).~5. Patient presents with motor complications which are, based on the investigator's judgment, not adequately controlled (i.e. a score ≥2 on one of the items of the MDS-UPDRS Part IV at screening)~6. Hoehn and Yahr stage \> 3~7. Evidence of disturbing (i.e. requiring treatment) impulse control disorder in the participant. Can be resolved through a structural interview during screening period.~8. History of neurosurgical intervention for PD~9. presence of symptomatic orthostatic hypotension at screening (MDS-UPDRS 1.12 \> 2)~10. Use of prohibited medication (e.g. benzodiazepines (except for clonazepam up to a maximum of 1.5 mg per d), lithium, opioids, buspirone, muscle relaxing agents, central nervous system depressing substances, ...)~11. Patients with laboratory values that are out-of-range at Screening (or within 4 weeks prior to Screening) and haven´t been reviewed and documented as not clinically significant by the investigator. Lab Tests can be repeated for confirmation.~12. Patients with known or newly diagnosed sinus tachycardia in ECG evaluation at Screening or within 4 weeks prior to Screening.~13. presence of an acute or chronic major psychiatric disorder (e.g., Major Depressive Disorder, psychosis) or symptom (e.g., hallucinations, agitation, paranoia) (MDS-UPDRS 1.2 and/or 1.3 \> 2)~14. Patients who had a recent suicidal attempt (active, interrupted, aborted) within the past five years or report suicidal ideation within the past 6 months.~15. presence of dementia (MDS-UPDRS 1.1 \> 2, Mini-Mental State Examination of \<24 at the Screening visit)~16. clinically significant or unstable medical or surgical condition at Screening or Baseline visit that may preclude safety and the completion of the study participation (based on the investigator's judgment).~17. Patients with moderate or severe hepatic or renal impairment.~18. Patient has a history of chronic alcohol or drug abuse within the last 2 years.~19. women of child-bearing potential who do not practice an acceptable method of birth control~20. Pregnant women or women planning to become pregnant during the course of the study and nursing women.~21. Patients who are knowingly hypersensitive to any of the components of the investigational medicinal product or excipients.~22. Patient is legally incapacitated or persons held in an institution by legal or official order~23. Persons with any kind of dependency on the investigator or employed by the Sponsor or investigator

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Treatment Group (Type: ACTIVE_COMPARATOR): Nabilone 0.25 mg
- Placebo Group (Type: PLACEBO_COMPARATOR): Placebo (corn starch)

Based on this trial design, predict the completion outcome and termination type (if applicable).